status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score.

Objective: To evaluate a relation between status and the Chemotherapy Response Score in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy and interval debulking surgery.

Methods: Data were retrospectively collected on patients with unresectable disease undergoing three or four cycles of neoadjuvant chemotherapy and interval debulking surgery at the Gynecologic Oncology Unit of the Catholic University of the Sacred Heart from January 2016 to December 2020. All patients were assessed for somatic mutation at diagnosis. The omental specimens obtained at the interval surgery were evaluated according to Bohm's Chemotherapy Response Score System.

Results: A total of 172 patients were included in the analysis, 69 (40%) patients were mutation carriers and 103 (60%) patients were wild type. In the wild-type group (), 73 (70.9%) patients had a Chemotherapy Response Score of 1 or 2 and 30 (29.1%) patients had a score of 3. In the carriers group (), 39 (56.5%) patients had a score of 1 or 2 and 30 (43.5%) patients had a score of 3. Among the group, those with a Chemotherapy Response Score of 3 had a prolonged median progression-free survival (22 vs 15 months, p=0.003). Among the carriers group, no differences were found (30 vs 27 months, p=0.55). No difference in overall survival was observed in either the carriers population (p=0.23) or the population (60 vs 44 months, p=0.06).

Conclusions: Patients with seem to achieve a score of 1, 2 or 3 with the same frequency. In contrast, patients with seem to have a score of 1 or 2 more frequently than a score of 3. In patients with , this score may not be an indicator of chemosensitivity.